Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 14, 2024
Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP TrialP H Patel, S Dreibe, A Reid, et al.
Breast (Edinburgh, Scotland)|March 18, 2026
Modification of RECIST 1.1 criteria for assessing response in breast tumours treated with radiation therapy using multiparametric breast MRI: Radiology and oncology perspectiveE Durie, M Morris, N A Healy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repairT R Shenoy, G Boysen, M Y Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2020
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancerM P Kolinsky, P Rescigno, D Bianchini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 2